Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo controlled, multi-center study of the pharmacodynamics/efficacy, tolerability, and pharmacokinetics of 3 fixed dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in patients with mild to moderate Alzheimer's disease

Next Previous
Trial Profile

A randomized, double-blind, placebo controlled, multi-center study of the pharmacodynamics/efficacy, tolerability, and pharmacokinetics of 3 fixed dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in patients with mild to moderate Alzheimer's disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RG 3487 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Memory Pharmaceuticals

    • Most Recent Events

    • 05 May 2008 The actual completion date for this trial is 1 Oct 2007.
    • 05 May 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 12 Jul 2007 Top-line results are expected in quarter 4, 2007.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top